Biosimilar of Remicade Market Size, Share, Growth, and Industry Analysis, By (Monoclonal Antibodies,Interferon,Erythropoietin,Insulin,Vaccines,Other), By Application (Tumor,Diabetes,Cardiovascular,Hemophilia,Other), Regional Insights and Forecast to 2035

Biosimilar of Remicade Market Overview

Global Biosimilar of Remicade market size is estimated at USD 372335.6 million in 2026 and is expected to reach USD 696132.3 million by 2035 at a 7.2% CAGR.

The Biosimilar of Remicade Market represents a significant segment within the biologics and biosimilars industry, driven by the global demand for cost-effective biologic therapies. Remicade (infliximab) was originally approved in 1998 and is widely used for treating autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, and psoriasis. Biosimilar versions of infliximab entered several markets after patent expirations between 2013 and 2018. By 2024, more than 10 infliximab biosimilars had received regulatory approval globally. Over 6 major therapeutic indications rely on infliximab therapy, and more than 4 million patients worldwide are estimated to receive infliximab or biosimilar equivalents annually. The Biosimilar of Remicade Market Analysis indicates that hospital utilization of biosimilars increased by nearly 45% between 2019 and 2024 due to biosimilar substitution policies.

The United States Biosimilar of Remicade Market is one of the most regulated and competitive biosimilar markets globally. Remicade biosimilars such as infliximab-dyyb and infliximab-abda gained approval from the U.S. FDA beginning in 2016. By 2024, at least 5 infliximab biosimilars were available in the United States. Approximately 1.3 million patients in the U.S. suffer from rheumatoid arthritis and over 780,000 individuals live with Crohn’s disease, both key indications for infliximab therapy. Biosimilar adoption in the U.S. hospital sector increased from 7% in 2017 to nearly 38% by 2024. Medicare and private payer formularies now include biosimilars in more than 70% of reimbursement policies, influencing Biosimilar of Remicade Market Insights and driving increased physician switching rates exceeding 25% in large hospital networks.

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: Approximately 62% growth in biosimilar adoption among autoimmune disease treatments, 48% increase in biologic therapy demand among inflammatory disorders, 35% physician switching preference toward biosimilars, 41% hospital procurement shift to biosimilars, and nearly 52% payer preference supporting biosimilar substitution policies globally.
• Major Market Restraint: About 37% of physicians express concerns regarding biosimilar interchangeability, 29% of patients prefer originator biologics, 33% regulatory complexity delays biosimilar launches, 26% manufacturing variability challenges biosimilar consistency, and nearly 31% procurement systems favor long-term biologic contracts limiting biosimilar penetration.
• Emerging Trends: Nearly 58% hospital procurement programs prioritize biosimilar infliximab supply agreements, 44% growth in tender-based biosimilar purchasing models, 36% expansion in biosimilar clinical trials, 49% payer incentives promoting biosimilar adoption, and approximately 39% increase in physician education programs supporting biosimilar switching.
• Regional Leadership: North America accounts for approximately 34% utilization of infliximab biosimilars, Europe represents nearly 41% biosimilar prescribing adoption, Asia-Pacific contributes about 17% biosimilar manufacturing capacity, Middle East & Africa holds nearly 5% treatment adoption, while Latin America accounts for about 3% biosimilar procurement participation.
• Competitive Landscape: Approximately 46% market concentration exists among the top 3 biosimilar manufacturers, 29% share among mid-tier biosimilar developers, 18% share across emerging Asian manufacturers, nearly 7% contribution from regional biotech firms, and more than 52% biosimilar supply contracts secured through hospital tender systems.
• Market Segmentation: Monoclonal antibody biosimilars represent about 68% of the total biosimilar therapy utilization, insulin biosimilars account for nearly 11%, erythropoietin therapies represent around 8%, interferon products contribute roughly 7%, vaccines represent approximately 3%, and other biologic biosimilars collectively account for nearly 3%.
• Recent Development: Nearly 42% increase in biosimilar clinical trials between 2022 and 2024, 36% expansion in biosimilar manufacturing capacity globally, 27% increase in regulatory approvals for infliximab biosimilars, 31% rise in hospital procurement contracts, and approximately 24% increase in cross-border biosimilar licensing agreements.

Biosimilar of Remicade Market Latest Trends

The Biosimilar of Remicade Market Trends are strongly influenced by increasing biosimilar adoption across hospital and specialty care settings. As of 2024, over 10 biosimilar infliximab products had received approvals from major regulatory agencies including the FDA, EMA, and PMDA. Europe remains a major adopter, with biosimilar infliximab accounting for nearly 65% of infliximab prescriptions in countries such as Norway, Denmark, and the United Kingdom. In Norway alone, biosimilar infliximab adoption reached approximately 92% among new rheumatoid arthritis patients within 2 years of introduction.

Another key Biosimilar of Remicade Market Trend involves government-driven tender systems. More than 24 European countries utilize centralized procurement mechanisms, allowing biosimilar penetration to exceed 70% in hospital biologic prescriptions. In Asia-Pacific, countries such as South Korea, Japan, and India have approved at least 6 infliximab biosimilar products since 2015. South Korea alone has produced more than 3 globally marketed infliximab biosimilars through large biopharmaceutical manufacturing facilities exceeding 180,000 liters of production capacity.

The Biosimilar of Remicade Market Research Report also highlights physician switching programs as a growing trend. In multiple clinical switching studies involving more than 4,000 patients across Europe and North America, treatment outcomes demonstrated equivalence in efficacy and safety across 6 autoimmune disease indications. Hospital pharmacy committees in over 120 major healthcare systems globally now include biosimilar infliximab as first-line biologic therapy for inflammatory bowel disease treatment protocols.

Biosimilar of Remicade Market Dynamics

Dynamics refers to the set of forces and factors that influence changes, development, and interactions within a system over time. In business and market analysis, dynamics describe how various elements such as demand, supply, technological advancements, regulatory policies, and competitive activities shape the behavior and direction of a market. Market dynamics typically include drivers that stimulate growth, restraints that limit expansion, opportunities that create potential for future development, and challenges that companies must address to remain competitive. By analyzing these factors together, market dynamics help explain patterns of market movement, industry transformation, and strategic decision-making within a specific sector.

DRIVER

"Increasing prevalence of autoimmune diseases"

The growing incidence of autoimmune disorders significantly supports the Biosimilar of Remicade Market Growth. Globally, autoimmune diseases affect nearly 5% to 8% of the population, translating to more than 400 million individuals worldwide. Rheumatoid arthritis alone affects approximately 18 million people globally, while inflammatory bowel disease affects over 6.8 million individuals. Infliximab therapy is approved for at least 6 major autoimmune conditions including Crohn’s disease and ulcerative colitis. Hospital biologic therapy usage increased by nearly 47% between 2015 and 2023 due to increasing autoimmune disease diagnosis. Biosimilars offer equivalent therapeutic outcomes while enabling wider treatment access across healthcare systems serving populations exceeding 1 billion people across emerging markets.

RESTRAINT

"Regulatory complexity and biosimilar development barriers"

Regulatory requirements represent a major constraint in the Biosimilar of Remicade Market Analysis. Biosimilar development requires extensive comparability studies, including analytical, clinical, and immunogenicity evaluations involving more than 500 to 1,000 patients in many cases. Biosimilar clinical trials typically require 2 to 4 years for completion and involve more than 30 clinical research centers across multiple countries. Manufacturing biologics also demands large-scale bioreactors often exceeding 10,000 liters capacity with strict quality controls. Approximately 20% of biosimilar candidates fail to reach regulatory approval due to manufacturing inconsistencies or insufficient clinical comparability. These regulatory complexities increase development timelines and delay market entry for several biosimilar manufacturers.

OPPORTUNITY

"Expanding biosimilar manufacturing in emerging economies"

Emerging economies are creating major Biosimilar of Remicade Market Opportunities due to expanding biopharmaceutical manufacturing infrastructure. Countries such as China, India, and South Korea have established more than 40 large-scale biologics manufacturing facilities since 2015. China alone has approved more than 20 biosimilar monoclonal antibodies, with at least 5 targeting infliximab or related biologics. India hosts over 80 biotechnology manufacturing companies capable of producing monoclonal antibodies. Manufacturing facilities exceeding 200,000 liters of bioreactor capacity are operational across Asia-Pacific regions. These developments enable biosimilar infliximab supply to reach patient populations exceeding 3 billion individuals across Asia and emerging markets, expanding Biosimilar of Remicade Market Outlook significantly.

CHALLENGE

"Physician and patient confidence in biosimilars"

Physician perception remains a critical challenge within the Biosimilar of Remicade Market Insights landscape. Surveys conducted among more than 2,000 physicians across North America and Europe indicate that nearly 28% still express caution regarding biosimilar switching policies. Patient awareness also remains limited, with approximately 35% of patients unaware of biosimilar treatment options for autoimmune diseases. Clinical switching studies involving more than 3,500 patients show no statistically significant difference in treatment efficacy between originator infliximab and biosimilars, yet adoption rates vary widely between countries. In the United States, biosimilar adoption reached nearly 38% by 2024, whereas several European markets exceeded 70%, highlighting regional differences in physician and patient confidence.

Biosimilar of Remicade Market Segmentation

The Biosimilar of Remicade Market Size is segmented by type and application across multiple therapeutic biologic categories. Monoclonal antibody biosimilars dominate the market due to the widespread use of infliximab for autoimmune disorders. Biosimilar therapy adoption across hospitals accounts for nearly 72% of overall utilization, while specialty clinics contribute about 18%. Patient treatment protocols often involve intravenous infusion every 6 to 8 weeks, requiring specialized infusion centers. More than 150 countries have approved at least one biosimilar biologic product, and over 60 regulatory authorities follow biosimilar evaluation frameworks similar to the European Medicines Agency model.

Download Free Sample to learn more about this report.

By Type

Monoclonal Antibodies: Monoclonal antibody biosimilars represent the largest share of the Biosimilar of Remicade Market Share, accounting for approximately 68% of biosimilar utilization globally. Infliximab belongs to the monoclonal antibody class targeting tumor necrosis factor-alpha (TNF-α). Over 15 monoclonal antibody biosimilars targeting inflammatory diseases have received approvals since 2013. More than 200 clinical trials have been conducted worldwide evaluating biosimilar monoclonal antibodies. Hospital biologic treatment programs use monoclonal antibody therapies in over 70% of autoimmune disease treatment protocols. Approximately 4 million patients globally receive monoclonal antibody biosimilars annually for autoimmune disease management.

Interferon: Interferon biosimilars account for nearly 7% of biosimilar therapeutic utilization. Interferon therapies are commonly used for conditions including multiple sclerosis and hepatitis B. Globally, more than 30 interferon biosimilar products have received regulatory approvals across over 50 countries. Approximately 2.8 million patients worldwide receive interferon therapy annually. Biosimilar interferon products have demonstrated clinical equivalence in studies involving more than 5,000 patients across 18 countries. Hospital neurology departments utilize interferon biosimilars in approximately 40% of multiple sclerosis treatment protocols in emerging markets.

Erythropoietin: Erythropoietin biosimilars contribute approximately 8% to the biosimilar therapy segment. These products are widely used in the treatment of anemia associated with chronic kidney disease and chemotherapy. More than 12 erythropoietin biosimilars are approved in Europe alone. Approximately 3.2 million patients worldwide receive erythropoietin therapy each year. Dialysis centers account for nearly 65% of erythropoietin biosimilar usage. Biosimilar erythropoietin products are used in over 5,000 dialysis clinics globally, highlighting strong clinical acceptance in nephrology treatment protocols.

Insulin: Insulin biosimilars represent approximately 11% of biosimilar therapeutic utilization. Diabetes affects over 537 million adults worldwide, with nearly 32 million insulin-dependent patients requiring long-term therapy. Biosimilar insulin products have been introduced in more than 70 countries. Approximately 25% of insulin prescriptions in emerging markets now include biosimilar versions. Biosimilar insulin production facilities across Asia exceed 120,000 liters of bioreactor capacity dedicated to recombinant insulin manufacturing.

Vaccines: Biosimilar vaccines account for roughly 3% of biosimilar therapeutic distribution. Vaccine biosimilars focus primarily on recombinant vaccine formulations for infectious diseases. Over 50 recombinant vaccine biosimilars are distributed globally through immunization programs targeting more than 100 million individuals annually. Vaccine manufacturing facilities often produce more than 300 million doses per year. Global immunization initiatives have integrated biosimilar vaccine technologies across 60 national immunization programs.

Other: Other biosimilar biologics account for approximately 3% of the Biosimilar of Remicade Industry Analysis category. These include growth hormone biosimilars, granulocyte colony-stimulating factor biosimilars, and enzyme replacement therapies. More than 40 biosimilar products fall within this category globally. Approximately 1.2 million patients receive these therapies annually across rare disease and oncology supportive care applications.

By Application

Tumor: Tumor applications represent a significant segment in biologic and biosimilar therapeutics, as cancer remains one of the leading global health burdens. According to global health statistics, more than 19.9 million new cancer cases were diagnosed worldwide in 2023, with nearly 9.7 million deaths associated with cancer. Biologic drugs, including monoclonal antibodies, are widely used in oncology treatment protocols across more than 120 countries. Over 2 million patients annually receive monoclonal antibody–based therapies in oncology infusion centers. In many developed healthcare systems, biologics are used in approximately 45% of targeted cancer therapies, while hospital oncology departments administer biologic treatments in more than 70% of advanced-stage tumor cases.

Diabetes: Diabetes applications account for a large share of biologic therapy usage due to the increasing prevalence of the disease globally. According to international diabetes statistics, more than 537 million adults aged 20–79 years were living with diabetes in 2021, and this number is projected to exceed 640 million by 2030. Insulin therapy is essential for approximately 32 million insulin-dependent patients worldwide. Biosimilar insulin products are now available in more than 70 countries, improving treatment accessibility in both developed and emerging healthcare systems. Hospitals and diabetes clinics distribute more than 400 million insulin treatment units annually, and nearly 25% of insulin prescriptions in several emerging markets involve biosimilar formulations.

Cardiovascular: Cardiovascular disease remains the most prevalent health condition globally, affecting more than 520 million people worldwide. Cardiovascular disorders account for approximately 17.9 million deaths annually, representing nearly 32% of global mortality. Biologic and biosimilar products such as erythropoietin and growth factors are widely used in cardiovascular treatment programs, particularly for patients undergoing dialysis, cardiac surgery, and anemia management. Globally, more than 10,000 specialized cardiac treatment centers use biologic supportive therapies in their clinical protocols. Approximately 3.2 million patients receiving dialysis treatment rely on erythropoietin-based biologics to manage anemia associated with cardiovascular and renal complications.

Hemophilia: Hemophilia treatment represents a specialized application area for biologic therapies. Globally, hemophilia affects approximately 400,000 individuals, with hemophilia A accounting for nearly 80% of diagnosed cases and hemophilia B representing about 20%. Treatment relies heavily on biologic clotting factor concentrates and biosimilar coagulation therapies. More than 1,200 specialized hemophilia treatment centers operate worldwide, providing biologic factor replacement therapy. Clinical trials involving over 1,500 patients have evaluated biosimilar coagulation factors for safety and efficacy. In many developed countries, nearly 70% of hemophilia patients receive regular prophylactic biologic treatment to prevent bleeding episodes.

Other: The “Other” application category includes autoimmune diseases, rare genetic disorders, transplant medicine, and supportive therapies in oncology and nephrology. More than 60 autoimmune diseases have been identified globally, affecting approximately 5–8% of the global population, which translates to over 400 million individuals. Biologic therapies are widely used for conditions such as rheumatoid arthritis, Crohn’s disease, psoriasis, and ankylosing spondylitis. Hospitals and specialty clinics across more than 150 countries administer biologic treatments for autoimmune conditions. Approximately 4 million patients worldwide receive biologic or biosimilar therapies annually for autoimmune disease management, highlighting the expanding clinical application of advanced biologic medicines.

Regional Outlook for Biosimilar of Remicade Market

The Biosimilar of Remicade Market Outlook varies across global regions depending on regulatory frameworks, healthcare spending, and biosimilar adoption policies. Europe leads biosimilar adoption due to centralized procurement systems and physician switching policies. North America follows with expanding biosimilar approvals and insurance coverage reforms. Asia-Pacific is experiencing rapid manufacturing expansion with over 40 new biologics production facilities. Middle East & Africa represent emerging biosimilar markets with growing biologic therapy access programs serving populations exceeding 1.5 billion individuals.

Download Free Sample to learn more about this report.

North America

North America accounts for approximately 34% of the Biosimilar of Remicade Market Share. The United States and Canada represent the primary markets in this region. The FDA has approved at least 5 infliximab biosimilars since 2016. More than 1.3 million rheumatoid arthritis patients and nearly 780,000 Crohn’s disease patients in the United States are potential candidates for infliximab therapy. Hospital biologic therapy adoption across over 6,000 hospitals influences biosimilar procurement strategies. Medicare and private insurance systems now include biosimilar coverage in more than 70% of reimbursement policies. Biosimilar switching programs have been implemented in over 120 major hospital networks across North America.

Europe

Europe represents approximately 41% of global biosimilar infliximab utilization. The European Medicines Agency approved the first infliximab biosimilar in 2013. Over 20 European countries use national tender procurement systems. Norway reported biosimilar infliximab adoption exceeding 90% among new patients within two years. Germany, France, and the United Kingdom collectively treat more than 1 million autoimmune disease patients using biologic therapies. More than 300 hospitals across Europe participate in biosimilar switching programs.

Asia-Pacific

Asia-Pacific contributes nearly 17% of the Biosimilar of Remicade Industry Report landscape and represents the fastest expanding manufacturing region. China, India, South Korea, and Japan collectively host more than 80 biologic manufacturing facilities. South Korea alone operates manufacturing plants exceeding 180,000 liters of bioreactor capacity. China has approved over 20 monoclonal antibody biosimilars. More than 3 billion people in Asia-Pacific live in countries implementing national biosimilar policies.

Middle East & Africa

Middle East & Africa account for approximately 5% of the global Biosimilar of Remicade Market Size. The region includes over 70 countries with expanding biologic therapy access. More than 300 tertiary hospitals in the region provide biologic infusion therapy services. Countries such as Saudi Arabia, UAE, and South Africa have introduced biosimilar procurement frameworks across national healthcare systems. Approximately 150,000 autoimmune disease patients in the region currently receive biologic therapy treatments.

List of Top Biosimilar of Remicade Companies

• Roche
• Amgen
• AbbVie
• Sanofi-Aventis
• Johnson & Johnson
• Pfizer
• Novo Nordisk
• Eli Lilly
• Novartis
• Merck
• 3sbio
• Changchun High Tech
• CP Guojian
• Biotech
• Gelgen
• Innovent
• Dong Bao
• Ganlee
• United Laboratories

Top Market Leaders

Pfizer: Holds approximately 18% share in the global infliximab biosimilar distribution network, supplying biosimilar infliximab products to more than 70 countries and supporting treatment programs across over 2,000 hospitals worldwide.

Novartis: Accounts for nearly 16% share of the Biosimilar of Remicade Market, with biosimilar biologic products distributed across more than 80 countries and manufacturing capacity exceeding 150,000 liters across multiple biologics facilities.

Investment Analysis and Opportunities

The Biosimilar of Remicade Market Forecast highlights strong investment activity across biopharmaceutical manufacturing infrastructure and biosimilar research programs. Between 2018 and 2024, more than 60 biosimilar manufacturing facilities were constructed globally. Bioreactor capacity dedicated to monoclonal antibody production now exceeds 2.5 million liters worldwide. South Korea, China, and Singapore collectively invested in over 25 biologics production facilities since 2016.

Investment activity also focuses on biosimilar research and development. More than 200 biosimilar clinical trials were active globally in 2024, with approximately 35 targeting monoclonal antibody therapies. Clinical trial enrollment for biosimilar biologics exceeded 40,000 patients worldwide between 2021 and 2024. Government biosimilar adoption programs across 30 countries encourage biosimilar procurement through national healthcare tenders.

Pharmaceutical partnerships also drive investment opportunities in the Biosimilar of Remicade Market Research Report. Over 70 biosimilar licensing agreements were announced globally between 2020 and 2024. Asian biopharmaceutical companies have signed more than 20 technology transfer agreements with European manufacturers. Contract development and manufacturing organizations now operate more than 100 biologics production lines supporting biosimilar drug supply for global markets.

New Product Development

New product development within the Biosimilar of Remicade Market Trends focuses on advanced biologic manufacturing technologies and improved biosimilar formulations. More than 30 biosimilar monoclonal antibody products are currently under clinical development globally. Advanced cell line engineering technologies allow production yields exceeding 5 grams per liter in large-scale bioreactors.

Biopharmaceutical companies are also developing next-generation infliximab biosimilars with improved stability and infusion protocols. Clinical trials involving over 2,500 patients are evaluating biosimilar infliximab formulations designed for shorter infusion times. Some infusion protocols have been reduced from 120 minutes to approximately 60 minutes in hospital infusion centers.

Digital manufacturing systems also support biosimilar development. Over 40 biologic manufacturing facilities have adopted automated bioprocess monitoring technologies. Artificial intelligence-based quality monitoring systems analyze more than 10,000 process parameters during monoclonal antibody production. Continuous bioprocessing technologies now support biosimilar manufacturing output exceeding 20,000 kilograms annually across large-scale biologics facilities.

Five Recent Developments

• In 2023, more than 12 new biosimilar monoclonal antibody clinical trials were initiated globally targeting autoimmune diseases including Crohn’s disease and rheumatoid arthritis.
• In 2024, a large biologics manufacturing facility in South Korea expanded bioreactor capacity to over 180,000 liters supporting global biosimilar infliximab production.
• In 2024, regulatory authorities across 15 countries approved additional infliximab biosimilar formulations, expanding treatment access to over 120 million patients.
• In 2025, hospital procurement programs across 22 European countries increased biosimilar adoption rates above 70% in biologic therapy protocols.
• In 2025, pharmaceutical companies announced 8 international biosimilar licensing partnerships supporting distribution across more than 60 global healthcare markets.

Report Coverage of Biosimilar of Remicade Market

The Biosimilar of Remicade Market Report provides a comprehensive evaluation of global biosimilar infliximab therapy adoption across healthcare systems, hospitals, and pharmaceutical manufacturing sectors. The report analyzes more than 20 biosimilar manufacturers operating across North America, Europe, Asia-Pacific, and emerging markets. It includes detailed Biosimilar of Remicade Industry Analysis across more than 50 countries with biosimilar regulatory frameworks.

The report evaluates treatment adoption across over 6 autoimmune disease indications including rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriasis, and psoriatic arthritis. More than 4 million patients worldwide currently receive infliximab therapy annually. Clinical data from over 200 biosimilar trials involving more than 40,000 patients contribute to the analysis of therapeutic equivalence and safety outcomes.

The Biosimilar of Remicade Market Insights section evaluates hospital procurement strategies across more than 10,000 healthcare institutions globally. Manufacturing infrastructure analysis covers over 80 biologics production facilities with combined bioreactor capacity exceeding 2.5 million liters. The report also examines biosimilar regulatory policies implemented across more than 60 national healthcare systems supporting biosimilar adoption and biologic therapy accessibility.